

Oral Biologics & Biosimilar Drugs Market Players Invest In Developing Biosimilars For Insulin


The Business Research Company's Oral Biologics & Biosimilar Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, February 10, 2022 /EINPresswire.com/ -- The latest trend in the [oral biologics and biosimilar market](#) is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. Following the trend, Mylan, a USA based pharmaceuticals company, in partnership with Biocon launched biosimilar insulin glargine named Semglee, in Australia. Biocon is an Indian based biopharmaceutical company. Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the global oral biologics & biosimilar drugs market are investing in the trend of developing biosimilar of insulin to gain profit.

Major players covered in the global oral biologics & biosimilar drugs industry are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline Plc., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche.

Read more on the Global Oral Biologics & Biosimilar Drugs Market Report:

<https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drugs-global-market-report>



Oral Biologics & Biosimilar Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

The global oral biologics & biosimilar drugs market size is expected to grow from \$4.06 billion in 2021 to \$4.91 billion in 2022 at a compound annual growth rate (CAGR) of 21%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oral biologics and biosimilar drugs market is expected to reach \$10.41 billion in 2026 at a CAGR of 20.7%.

The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics & biosimilar drugs market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the oral biologics & biosimilar drugs market.

North America was the largest region in the oral biologics and biosimilar drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

TBRC's global oral biologics & biosimilar drugs market research report is segmented by therapy into lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors, by disease into asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis and others, by molecule type into vaccines, proteins & peptides, monoclonal antibodies, others, by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.

[Oral Biologics & Biosimilar Drugs Global Market Report 2022](#) – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a oral biologics & biosimilar drugs market overview, forecast oral biologics & biosimilar drugs market size and growth for the whole market, oral biologics & biosimilar drugs market segments, geographies, oral biologics & biosimilar drugs market trends, oral biologics & biosimilar drugs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Oral Biologics & Biosimilar Drugs Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Biosimilar Monoclonal Antibodies Global Market Report 2021 - By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change>

Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/biologics-global-market-report>

Biosimilar Therapeutic Peptides Global Market Report 2022 – By Route Of Administration (Parenteral Route, Transdermal Route), By Application (Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders), By Type (Innovative, Generic) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptides-global-market-report>

About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/562776776>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.